RxDoctor Payments Data

Rachelina Kvietkus, MD

Internal Medicine · South Bend, INNPI 1376586420

Payments from drug & device makers

$1,676in general payments, 2019–2025

Across 41 payments — averaging $40.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$467
  • Insulet Corporation$211
  • Novartis$199
  • Novo Nordisk$194
  • AbbVie$187
  • AstraZeneca$125
  • plus $293 from 7 others

What the payments were for

  • Food & beverage$1,62997%
  • Education$191%
  • Other$292%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,676 in reported general payments places this provider in the 80th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$249,978
Medicare patients
364
Services billed
6,269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$91,385
MounjaroTirzepatide65$72,755
JanuviaSitagliptin Phosphate59$62,998
OzempicSemaglutide33$31,936
JardianceEmpagliflozin26$31,460
XareltoRivaroxaban13$20,720
Breo ElliptaFluticasone/Vilanterol36$13,987
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$13,109
Tresiba Flextouch U-100Insulin Degludec19$10,739
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,136
TradjentaLinagliptin11$6,559
MyrbetriqMirabegron12$6,430
Atorvastatin Calcium747$5,172
SynthroidLevothyroxine Sodium80$4,676
Novolog FlexpenInsulin Aspart24$4,675

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$467$72,75565 claims
Boehringer IngelheimJardiance, Tradjenta$40$38,01937 claims
Novo NordiskOzempic$194$31,93633 claims
AbbVieSynthroid$187$4,67680 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in South Bend

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →